XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
B
B

Biogen

News

Reuters - 13 hours ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 23 hours ago

Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen

BUZZ-Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen ** The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's under the brand name Kisunla, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients *
B
Reuters - 2 days ago

Eli Lilly Alzheimer's drug approved by US FDA

UPDATE 3-Eli Lilly Alzheimer's drug approved by US FDA Adds Leqembi comparison, expert and analyst comments in paragraphs 5-16 By Julie Steenhuysen and Mariam Sunny July 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S.
B
Reuters - 4 days ago

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japan's Eisai developing dementia drug for US market, Nikkei reports TOKYO, June 30 (Reuters) - Japanese drugmaker Eisai 4523.T is developing a d ementia treatment that it aims to commerciali s e in the U.S. by fiscal 2030, the Nikke i r eported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
B
Reuters - 6 days ago

Eisai and Biogen launch Alzheimer's drug Leqembi in China

Eisai and Biogen launch Alzheimer's drug Leqembi in China June 28 (Reuters) - Eisai 4523.T and Biogen BIOAb.ST have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
B
Reuters - 1 week ago

Biogen has up to $10 billion for its next M&A bets- Bloomberg News

MEDIA-Biogen has up to $10 billion for its next M&A bets- Bloomberg News -- Source link: https://tinyurl.com/3w57zmcr -- Note: Reuters has not verified this story and does not vouch for its accuracy
B
Reuters - 1 week ago

Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union

BRIEF-Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union June 24 (Reuters) - Biogen Inc BIIB.O : TOFIDENCE™ (TOCILIZUMAB), A BIOSIMILAR REFERENCING ROACTEMRA®, APPROVED IN THE EUROPEAN UNION Source text for Eikon: ID:nGNE95yLRY Further company coverage: BIIB.O
B
Reuters - 2 weeks ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +6.8% Tesla Inc TSLA.OQ +5.8% Broadcom Inc AVGO.OQ +5.7% Micron Technology Inc MU.OQ +4.7% Synopsys Inc SNPS.OQ +4.0% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -3.2% Atlassian Corp TEAM.OQ -2.4% Biogen Inc BIIB.OQ -2.2% ON Semiconductor Corp ON.OQ -2.0% Marvell Technology Inc MRVL.OQ -1.8% The Nasdaq 100 .NDX gained 287.51 points, or
A
B
B
M
M
T
W
O
U
A
S
Reuters - 3 weeks ago

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds By Christy Santhosh June 13(Reuters) - Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on Thursday. The report issued by the U.S.
B
Reuters - 3 weeks ago

Biogen executive plays down looming competition for its Alzheimer's drug

UPDATE 1-Biogen executive plays down looming competition for its Alzheimer's drug Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11 By Sriparna Roy June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
B
G
Reuters - 3 weeks ago

Biogen executive says its Alzheimer's drug will do well in market despite competition

Biogen executive says its Alzheimer's drug will do well in market despite competition June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editi
B
Reuters - 3 weeks ago

Alzheimer's is a $100 bln pharma opportunity, says HSBC

BUZZ-Alzheimer's is a $100 bln pharma opportunity, says HSBC ** Brokerage HSBC says Biogen BIIB.O and partner Eisai's 4523.T Leqembi and Eli Lilly's LLY.N donanemab could start shaping a $100 bln U.S. market for Alzheimer's disease treatments ** Leqembi was given full approval by the U.S. FDA last year and donanemab won an unanimous endorsement by an advisory panel on Monday ** HSBC says overwhelming support for donanemab's approval highlights not only a positive benefit-risk profile for the new
B
Reuters - 3 weeks ago

Japan's Nikkei gains on chip shares boost; Fed policy in focus

Japan's Nikkei gains on chip shares boost; Fed policy in focus Updates with closing levels By Brigid Riley TOKYO, June 11 (Reuters) - Japan's Nikkei share average closed at a two-month peak on Tuesday as heavyweight chip shares tracked their Wall Street peers higher, while investors braced for the Federal Reserve's p olicy decision later this week . S entiment was up during early Tokyo trading after the S&P 500 and Nasdaq both logged record closing highs overnight .
B
U
J
U
Reuters - 3 weeks ago

FDA advisory panel backs Lilly Alzheimer's drug

FDA advisory panel backs Lilly Alzheimer's drug June 10(Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration voted unanimously on Monday to back Eli Lilly's LLY.N experimental Alzheimer's drug, donanemab, saying its benefits outweigh risks posed by the treatment. Lilly's drug is a potential rival to Eisai 4523.T and Biogen's BIIB.O Leqembi, which won U.S.
B
Reuters - 3 weeks ago

Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel

UPDATE 5-Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel Adds final vote in first paragraph, details from panel meeting throughout, comments in paragraphs 3 and 20, share move By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's LLY.N experimental Alzheimer's treatment donanemab outweighed its risks, and agreed that trial data showed it was effective
B
Reuters - 3 weeks ago

US FDA advisers to review Eli Lilly Alzheimer's drug

US FDA advisers to review Eli Lilly Alzheimer's drug By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's LLY.N experimental Alzheimer's drug donanemab. Donanemab, if approved, would compete with Eisai 4523.T and Biogen's BIIB.O Leqembi.
B
Reuters - 3 weeks ago

Eisai Says FDA Accepts Co's Filing Of Leqembi® Supplemental Biologics License Application For IV Maintenance Dosing

BRIEF-Eisai Says FDA Accepts Co's Filing Of Leqembi® Supplemental Biologics License Application For IV Maintenance Dosing June 9 (Reuters) - Biogen Inc BIIB.O : FDA ACCEPTS EISAI'S FILING OF LEQEMBI® (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR IV MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE EISAI- PDUFA AC
B
Reuters - 4 weeks ago

What to Watch in the Week Ahead and on Monday, June 10

What to Watch in the Week Ahead and on Monday, June 10 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Morgan Stanley CEO Ted Pick is scheduled to speak at the bank's annual U.S.
A
B
B
C
D
T
A
B
Reuters - 4 weeks ago

US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

UPDATE 3-US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug Adds details from FDA, Lilly documents in paragraphs 9, 11-16, 18-19, analyst comment in paragraph 17 By Bhanvi Satija and Julie Steenhuysen June 6 (Reuters) - An FDA analysis of trial data for Eli Lilly's LLY.N experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
B
Reuters - 4 weeks ago

US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug

US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug June 6 (Reuters) - A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly's LLY.N experimental treatment, donanemab, shows it is effective for treating patients with early Alzheimer's disease. The panel will also vote on whether benefits of the treatment outweigh its risks, according to documents published on the agency's website.
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.